Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹445 Cr
verified against source
Revenue YoY
7.9%
reported change
EBITDA
₹31.5 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Indoco Remedies reported a mixed Q3 FY26. Consolidated revenue grew 7.9% YoY to ₹434.3 crore, driven by strong export performance (international formulations +26.2%, APIs +24%). Domestic formulation revenue was flat at ₹201.4 crore due to acute therapy weakness, though secondary sales remained healthy. EBITDA margin expanded 430 bps YoY to 7.3%, aided by improved subsidiary performance and cost controls, but included ~₹8-9 crore one-time remediation costs. Management guided for a stronger Q4 in Europe as customer approvals finalize, and expects US business to benefit from new product launches at FPP. Key risks include delayed USFDA resolution for Goa Plant 2 and elevated debt of ~₹920 crore, though deleveraging is underway with planned repayments of ₹135-140 crore annually.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects European revenues to grow at over 20% annually, driven by new product approvals and site optimization, with margins improving.
- Warren Remedies' OTC business, currently at ~₹130 crore annual run-rate, is expected to grow at least 30% in FY27 due to new launches and increased consumer marketing.
- Management guided for maintenance capex of ₹35-40 crore annually over the next 2-3 years, with no major new capex planned.
- Total debt of ~₹920 crore is expected to reduce to ₹775-800 crore by March 2027, with annual repayments of ₹135-140 crore funded by internal cash flows.
Risks flagged
- The USFDA warning letter for Goa Plant 2 remains unresolved, limiting sterile product sales and requiring costly remediation and technology transfers.
- Consolidated debt of ~₹920 crore requires annual repayments of ₹135-140 crore, which may strain cash flows if growth disappoints.
- Domestic formulation revenue was flat due to unpredictable acute therapy demand, and management expressed uncertainty about near-term recovery.
- European growth was pushed back by one quarter due to customer approval delays, and management noted that 90% of work is done but timing remains uncertain.
Key quotes
- We have jumped one rank and are now ranked 21st in the prescription audit with a total of 10.86 crore prescriptions and we have jumped over Pfizer.
- I'm not just looking at topline growth but we should look at Europe over the next few years as growing at 20% plus in revenues but more importantly we should be watching the margins to improve on that business.
- When it comes to Warren Remedies, let them breathe and grow sales.
Research modules